A catalog of prostate cancer nomograms

Journal of Urology

Volumn 165, Issue 5 I, 2001, Pages 1562-1568

  Ross, Phillip L ^a   Scardino, Peter T ^a   Kattan, Michael W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Forecasting; Prognosis; Prostate; Prostatic neoplasms

Indexed keywords

ADULT; AGED; ARTICLE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; NOMOGRAM; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY OF LIFE; TREATMENT PLANNING; TUMOR LOCALIZATION;

EID: 0035043408     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)66349-5     Document Type: Article

References (50)

1. Cancer statistics, 2000
2. Causes and effects of my disturbing little book
3. A leisurely look at the bootstrap, the jackknife, and cross-validation
4. A decision analysis for treatment of clinically localized prostate cancer
5. Clinical states in prostate cancer: Toward a dynamic model of disease progression
6. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma
7. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer
8. Consensus statement: Guidelines for PSA following radiation therapy
9. The definition of biochemical failure in patients treated with definitive radio-therapy
10. Comparing tumor staging and grading systems: A case study and a review of the issues, using thymoma as a model
11. Clinical versus actuarial judgment
12. Distinguishing clinically important from unimportant prostate cancers before treatment: Value of systematic biopsies
13. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
14. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate
15. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer
16. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
17. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update
18. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer
19. Predicting the pathology results of radical prostatectomy from preoperative information: A validation study
20. Evaluation of ProstAsure index in the detection of prostate cancer: A preliminary report
21. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: Results on 4298 cases
22. Artificial neural networks in the diagnosis, and prognosis of prostate cancer: A pilot study
23. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer
24. Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens
25. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer
26. Predicting extracapsular extension of prostate cancer in men treated with radical prostatectomy: Results from the population based prostate cancer outcomes study
27. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level
28. Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens
29. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy
30. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer
31. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer
32. Site specific predictors of positive margins at radical prostatectomy: An argument for risk based modification of technique
33. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer
34. Early prostate-specific antigen relapse after radical retropubic prostatectomy: Prediction on the basis of preoperative and postoperative tumor characteristics
35. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer
36. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
37. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
38. Identification of intermediate-risk prostate cancer patients treated with radio-therapy suitable for neoadjuvant hormone studies
39. An enhanced prognostic system for clinically localized carcinoma of the prostate
40. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis
41. Prognostic factors for clinically localized prostate carcinoma: Analysis of 938 patients irradiated in the prostate specific antigen era
42. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma
43. Prostate cancer is highly predictable: A prognostic equation based on all morphological variables in radical prostatectomy specimens
44. The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer
45. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy
46. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy
47. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer
48. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases
49. Natural history of progression after PSA elevation following radical prostatectomy